Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Molecular Biology|October 27, 2019
Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XIMartina Schaefer, Anja Buchmueller, Frank Dittmer, et al.Developmental Biology|December 2, 2006
Compartmentalization of a unique ADP/ATP carrier protein SFEC (Sperm Flagellar Energy Carrier, AAC4) with glycolytic enzymes in the fibrous sheath of the human sperm flagellar principal pieceYoung-Hwan Kim, Gerhard Haidl, Martina Schaefer, et al.Acta Crystallographica. Section D, Structural Biology|August 29, 2024
Surface-mutagenesis strategies to enable structural biology crystallization platformsMartina Schaefer, Vera Pütter, André Hilpmann, et al.Biochemistry|April 26, 2013
Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexesVijay Kumar, Faye Martin, Michael G Hahn, et al.The Journal of Biological Chemistry|May 14, 2010
Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclaseFaye Martin, Padmamalini Baskaran, Xiaolei Ma, et al.Acta Crystallographica. Section F, Structural Biology Communications|May 18, 2026
Structural analysis of the flexibility of the Ubl2 domain within the papain-like protease of SARS-CoV-2Gian Luca Freiherr von Scholley, Martina Schaefer, Mark D Tully, et al.Journal of Medicinal Chemistry|October 27, 2020
Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral PharmacokineticsAlexander Hillisch, Kersten M Gericke, Swen Allerheiligen, et al.Critical Care (London, England)|May 1, 2014
Immunomodulation by fish-oil containing lipid emulsions in murine acute respiratory distress syndromeMatthias Hecker, Juliane Ott, Christoph Sondermann, et al.Journal of Medicinal Chemistry|September 5, 2023
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic DisordersSusanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez, et al.Journal of Medicinal Chemistry|February 13, 2024
BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 InhibitorDaniel Meibom, Pierre Wasnaire, Kristin Beyer, et al.Pageof 2